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Abstract
Multidrug-resistant and rifampicin-resistant tuberculosis (MDR/RR-TB) represent an important challenge for global
tuberculosis (TB) control. The high rates of MDR/RR-TB observed among re-treatment cases can arise from diverse
pathways: de novo amplification during initial treatment, inappropriate treatment of undiagnosed MDR/RR-TB,
relapse despite appropriate treatment, or reinfection with MDR/RR-TB. Mathematical modelling allows quantification
of the contribution made by these pathways in different settings. This information provides valuable insights for TB
policy-makers, allowing better contextualised solutions. However, mathematical modelling outputs need to consider
local data and be easily accessible to decision makers in order to improve their usefulness. We present a
user-friendly web-based modelling interface, which can be used by people without technical knowledge. Users can
input their own parameter values and produce estimates for their specific setting. This innovative tool provides easy
access to mathematical modelling outputs that are highly relevant to national TB control programs. In future, the
same approach could be applied to a variety of modelling applications, enhancing local decision making.
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The threat of drug-resistant TB
Drug-resistant tuberculosis (TB) is a threat to TB control
and a barrier to disease elimination. TB treatment is com-
plicated by resistance to rifampicin and/or isoniazid, the
two most active first-line TB drugs. At the global level,
3.9% (95% confidence interval [CI]: 2.7–5.1%) of all new
TB cases are multidrug-resistant (defined as resistant to at
least rifampicin and isoniazid) or rifampicin-resistant
(MDR/RR-TB). However, the proportion of MDR/RR-TB
globally is even higher among re-treatment cases, reaching
21% (95% CI: 15–28%) according to estimates by the
World Health Organization (WHO) [1]. Mathematical
modelling suggests that MDR-TB strains could become
dominant over the drug-susceptible (DS) ones in the com-
ing decades [2], threatening the success of WHO’s End TB
Strategy and targets for TB elimination. A more compre-
hensive understanding of the different mechanisms
leading to MDR/RR-TB at re-treatment is important to
provide enhanced insight into the local determinants of
drug-resistant TB emergence and to support the develop-
ment of better contextualised solutions.
The pathways to drug resistance at re-treatment
The higher proportion of MDR/RR-TB in re-treatment
cases compared to new cases has long been attributed to
resistance amplification due to poor treatment adherence,
focusing the response to emergent drug-resistant TB on
better treatment supervision of patients treated with first-
line therapy [3, 4]. Among re-treated cases, finding of
MDR/RR-TB rarely triggers consideration of pathways that
involve primary transmission of drug-resistant strains, i.e.
involving infection with an already drug-resistant pathogen.
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However, three different causal pathways to MDR/RR-TB
at re-treatment can be identified that do not involve resist-
ance amplification and are therefore illustrations of primary
transmission. First, the low rate of drug susceptibility
testing among new TB cases results in a large proportion of
initially drug-resistant cases being treated with inappropri-
ate regimens, leading to treatment failure or disease relapse
and re-presentation as a “re-treatment case” [1]. In
addition, among new cases correctly diagnosed with MDR/
RR-TB, treatment outcomes are often unfavourable, making
resistant cases more likely to present for re-treatment. Fi-
nally, reinfection with a drug-resistant strain may also con-
tribute to the burden of MDR/RR-TB seen at re-treatment,
especially in settings where TB transmission is poorly
controlled. We developed a modelling approach to quantify
the likely proportions of MDR/RR-TB at re-treatment
attributed to the different causal pathways specified [5].
Findings highlighted the failure to identify drug resistance
at first presentation as a leading source of MDR/RR-TB
among re-treatment cases at the global level. However,
when applying our model to different regions and coun-
tries, we demonstrated substantial variability in the respect-
ive contributions of the various sources at the national and
local levels. This finding highlights the need for better con-
textualised solutions that utilise local data to guide local TB
control priorities and interventions.
The need to make mathematical modelling more
applicable and usable
While our previous study provided estimates at the national
level for more than 100 countries, detailed assessment of the
dominant drug resistance pathways in specific settings
would assist local control efforts. Strong spatial heterogen-
eity in the burden of MDR/RR-TB has been identified in
several countries [6–9], with demonstration that transmis-
sion can reach extreme intensities in small localities [10],
emphasising the need for better contextualised solutions. In
such settings, refined estimates incorporating local informa-
tion would be invaluable in producing realistic and action-
able model outputs. Estimates reported in our previous
study only provided insight relevant to 2015 data, as re-
ported in the 2016 WHO Global Tuberculosis Report [1].
However, this fails to take account of the changing aspects
of the TB epidemic and the need for real-time decision mak-
ing in order to optimize programmatic responses. Allowing
real-time assessment of likely MDR/RR-TB pathways will
provide updated estimates as routine data are gathered and
refreshed over time. In addition, policy makers may wish to
test alternate assumptions or to use parameter values that
they believe more appropriate. Such continuity and flexibil-
ity cannot be provided by occasional external expert support
or traditional research project-based approaches, and thus
represent a major barrier to the effective use of mathemat-
ical modelling for everyday policy guidance.
To overcome this limitation, present in most modelling
outputs reported to date, we developed a user-friendly
interface for real-time analysis of local data using our re-
cently published model of MDR/RR-TB pathways [5]. In
the current paper we introduce a web-based interactive
tool to quantify the likely contribution of different MDR/
RR-TB pathways among re-treatment cases, accommodat-
ing localised parameterisation via a user-friendly interface.
The user-friendly modelling interface
General description
The user interface is available online at www.tb-model-
ling.com/mdr_tb_at_retreatment. Its main objective is to
quantify the proportions of MDR/RR-TB at re-treatment
attributed to four principle causal pathways: I) initial
drug-susceptible TB with resistance amplification during
treatment; II) initial MDR/RR-TB inappropriately treated
as drug-susceptible TB; III) MDR/RR-TB relapse despite
appropriate treatment; and IV) re-infection with MDR/
RR-TB. The model employed to estimate these contribu-
tions was described in detail in our previous publication
[5]. The online tool allows users to produce estimates by
using the model in combination with their own inputs.
The associated model outputs are produced in real time
and exporting features allow the user to download perso-
nalised reports in a PDF format. Figure 1 summarises the
general principle and the different functionalities of the
platform. Javascript language was used to build the inter-
active platform as we needed immediate responsiveness to
produce model outputs instantaneously when users
specify new inputs. Thus, the webpage is only loaded once
from the remote server and calculations are then per-
formed on the user’s device in real time when parameter
values are changed. We used Chart, jVectorMap and
jsPDF libraries to generate the charts, maps and exporting
functionalities, respectively.
Personalised inputs
The user must specify the area (WHO region or country)
to which the model will apply. This process allows prese-
lected parameter sets to be generated based on local
WHO data. While these default values correspond to the
ones that were used in the initial study [5], they can here
be adjusted using a set of slider bars. Parameters are
classified into two main categories: ‘area-specific’ and
‘global’, with only parameters of the first category updated
when a new area is selected. Compatibility tests on param-
eter values are run in the background to ensure that the
parameterisation remains realistic. For example, if the user
selected a treatment success rate for DS-TB of 80%, a
ceiling is set for the death proportion during treatment for
DS-TB at 20%.
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Model outputs
The Model Outputs panel consists of two charts that are
automatically updated when any of the parameter values is
modified. First, a doughnut chart represents the propor-
tions of MDR/RR-TB at re-treatment attributed to the four
principle causal pathways I-IV. Second, a bar chart displays
the proportion of MDR/RR-TB among all re-treatment TB
cases. A comparison between the model output and the
WHO estimate regarding this proportion is also presented
on the second chart when relevant data are available from
WHO for the selected area. Quantitative estimates are dis-
played when the user moves the pointer over the different
shares of the two charts. Figure 2 presents a screen capture
of the interface containing the Inputs and Model Outputs
panels for an example model estimation.
Mapping
An interactive world map is incorporated in the user inter-
face to provide a global visualisation of the different
country-level estimates. The user can select one of the six
model outputs that can be displayed on the choropleth
map: individual contribution of Cause I, II, III or IV; leading
cause of MDR/RR-TB at re-treatment; and proportion of
MDR/RR-TB among all re-treatment TB cases. The results
presented on the maps are calculated using the user-
defined values for the global parameters and the default
values for the area-specific parameters. That is, changes to
the area-specific parameter values associated with a
selected country will not affect the maps (see Fig. 1). When
the user clicks on a country, the Inputs panel will be
updated and theModel Outputs panel will display estimates
related to the selected country.
Download personalised reports
Exporting functionalities are available allowing the users to
download PDF documents incorporating the model outputs
associated with their own parameterisation. Two different
types of report can be produced: one including the charts as
displayed in the Model Outputs panel and one containing
the selected map. The values of the parameters that are de-
fined by the user also appear in the generated documents.
Discussion
We introduce a user-friendly online tool capable of quanti-
fying the proportions of MDR/RR-TB at re-treatment
attributed to different causal pathways. This interface will
help policy-makers to better identify the pathways to drug
resistance and to design tailored programs to fight drug-
resistant TB. While the higher rates of MDR/RR-TB at
re-treatment by comparison to new cases have long been
recognised and reported by WHO, the pathways leading to
such gaps and their implications for effective local control
strategies have remained unexplored for too long. Our find-
ings suggest that primary transmission of drug-resistant
Fig. 1 General description of the user interface
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strains is the predominant pathway in most settings. This
challenges the old dogma that drug resistance amplification
as a result of poor quality or adherence to treatment was
the main explanation for the high rates of MDR/RR-TB at
re-treatment. It highlights the need to refocus TB control
interventions towards solutions that are specific to the
drivers of MDR/RR-TB in a particular location.
The modelling interface presented in this report will
enhance the applicability of this finding and we believe that
it provides an important “proof of principle” of how model-
ling approaches can be adapted to provide a user-friendly
interface for assisting local decision making. In this instance
it could assist countries to estimate the contribution of
different pathways to the generation of drug resistant TB
cases, allowing for better targeted and better contextualized
interventions to be considered. For example, finding high
proportion of MDR/RR-TB at re-treatment arising from
pre-existing MDR/RR-TB primary transmission may lead
to a response to universally test all new cases of TB for
resistance, whereas a finding of acquired amplification of
MDR/RR-TB being the dominant source may lead to exam-
ination of the failure/loss to follow-up rates of those with
DS-TB. As a “proof of principle” this tool demonstrates
how user-friendly interfaces can be developed to allow
public health decision makers, at different levels of care, ac-
cess to modelling data that is relevant to their local setting.
The platform allows our existing model to be used in
combination with flexible parameterisation entered by the
user. In addition to offering the possibility for alternate
parameter sets from those employed in our previous
study, this interface also allows estimates to be obtained
for a broader range of settings, and in particular at local
levels. Most importantly, this tool will allow users with no
specific technical knowledge to use a mathematical model
and to compute personalised estimates.
We chose not to include uncertainty around parameter
values when building this online interface in order to maxi-
mise the tool’s simplicity and to make it accessible to the
broadest possible audience. Nevertheless, the users will be
able to assess the sensitivity of the model estimates to the
different parameters by using the different input sliders and
produce outputs related to alternate parameter sets. In
contrast, our previous study incorporated uncertainty and
sensitivity analyses that highlighted the influence of some
parameters on the contributions of the respective pathways
[5]. In particular, we demonstrated that the contribution of
inappropriate diagnosis to the burden of MDR/RR-TB at
re-treatment was significantly affected when varying the
Fig. 2 Partial screen capture of the user interface. The Inputs panel contains the predefined parameter values associated with Viet Nam. The results
displayed in the Model Outputs panel are instantaneously updated when any of the parameters is adjusted through the sliders of the Inputs panel
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rate of drug susceptibility testing or the parameters that
relate to treatment outcomes (success and death rates).
Further, we noted that the contribution of the pathway
involving drug resistance amplification increased when re-
ducing the treatment success rate for DS-TB and the
individual-level risk of drug resistance amplification in un-
successfully treated patients. Other conceptual assumptions
than those considered in the baseline analysis may also be
explored using the sliders. For example, patients who are
lost to follow-up are assumed to experience unsuccessful
treatment under the default behaviour of our model but
alternate scenarios may be considered by increasing the
parameter values that define the treatment success rates.
The web-based tool addresses some of the limitations of
the original model, especially regarding the level of reso-
lution of the analysis and the uncertainty around param-
eter values and underlying assumptions. However, some
limitations that are linked to the intrinsic structure of the
model could not be addressed here. For example, only two
phenotypes of TB are considered in the model – DS-TB
and MDR/RR-TB – although we know that other resist-
ance profiles exist. This simplification was made in order
to make the model broadly applicable and to match with
the approach used by WHO to classify drug-resistant TB.
Another limitation is that some more specific causal path-
ways such as nosocomial transmission of MDR/RR-TB are
not considered in the model although there is evidence of
their importance in some settings [11, 12]. More specific
model structures may be designed to investigate the
causes of MDR/RR-TB among re-treatment cases in such
contexts. It is also important to note that the estimates
provided by our interface are relative contributions of the
different pathways expressed as percentage of the total
burden of MDR/RR-TB at re-treatment. Therefore, the
overall absolute burden of MDR/RR-TB at re-treatment
should also be taken into account by users if they wished
to estimate the absolute number of cases that are attrib-
uted to each of the four causal pathways.
User-friendly tools such as ours can contribute to build-
ing confidence in the use of modelling, which is essential
to facilitate the bidirectional exchange between modellers
and TB control program developers and improve the un-
derstanding of the local epidemic. We believe that this
user-friendly adaptation presents an important exemplar
of how modelling approaches could become more useful
to guide everyday decision making processes using local
data inputs for optimal contextualisation.
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